Press Releases

 

Company News

  Date Title and Summary View
Nov 30, 2016
LAWRENCEVILLE, N.J., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) for primary liver cancer (the OPTIMA Study), the study's Data Mo...
Nov 29, 2016
NIH Analysis of Data from Celsion's HEAT Study Reaffirms Correlation Between Increased RFA Burn Time per Tumor Volume and Significant Improvements in Overall Survival Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit for Patients Treated with ThermoDox® Plus Optimized RFA Compared with Optimiz...
Nov 10, 2016
Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care Top Line Translational Data from First Two Cohorts Demonstrates Potential Immune Activation LAWRENCEVILLE, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Celsion Corp...
Nov 10, 2016
Meaningful Progress with the ThermoDox® OPTIMA Study and GEN-1 Immunotherapy Program, Including Highly Encouraging Data from Primary Liver and Ovarian Cancer Studies Company to Hold Conference Call Today, November 10, 2016 at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an onco...
Nov 4, 2016
LAWRENCEVILLE, N.J., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office (USPTO) has granted two patents: Patent No. 9,468,687 B2 - Immuno Gene Therapy for Treatment of Cancer and Hyperproliferative Diseases, whi...
Nov 3, 2016
LAWRENCEVILLE, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and nine-month period ended September 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated lipo...
Oct 31, 2016
LAWRENCEVILLE, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study, highlighting the curative potential for ThermoDox® plus optimized radiofrequency ablation (RFA) in intermediate primary liver cancer, also know...
Oct 11, 2016
First Ever Clinical Trial in Children Using a Targeted Chemotherapeutic Drug Released by Focused Ultrasound Expected to Commence in Q4 2016  Initiation of this NIH-funded Study follows the Recent Announcement of NIH's Finding That Thermal Dose Appears to Improve Overall Survival in Primary Liver Cancer Patients Treated with ThermoDox® L...
Sep 15, 2016
LAWRENCEVILLE, N.J., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first three patient cohorts in the ongoing Phase Ib OVATION Study.  Based on the DSMB's recommendation, the study will continue as plann...
Sep 12, 2016
Conclusions Drawn from Results of Celsion's HEAT Study Prompted NIH Analysis; Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit Compared to Treatment with RFA Alone Abstract Accepted for Oral Presentation at the 2016 RSNA Annual Meeting LAWRENCEVILLE, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) -- ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Share This